Clinical Trial ResultsCAN-2409 showed an 80.4% complete response vs 63.6% complete response in the control arm, indicating a strong efficacy in treating prostate cancer.
Market PotentialCAN-2409 introduces a new treatment paradigm for early-stage prostate cancer, targeting urologists and radiation oncologists, which could expand its market reach.
Regulatory ProgressThe BLA submission for CAN-2409 in prostate cancer is on track for completion, and the chance of approval is viewed as high, given the reported data.